All News

In this interview we discuss the new American Cancer Society breast cancer screening guidelines and find out how they stack up with other recommendations for mammography screening.

In this November news roundup we highlight some of the top stories of the month, including several FDA approvals, new breast cancer guidelines, and more.

Today the FDA approved the PD-1 inhibitor nivolumab (Opdivo) as a single-agent frontline treatment for patients with BRAF wild-type advanced melanoma.

Innovative “adaptive” clinical trial designs are using molecular tools and biomarkers in ways that will streamline research efforts and bring new treatments more quickly to regulatory approval and clinical use.

Expression of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) is associated with poor glioblastoma outcomes.

The table of contents for the latest issue of the journal ONCOLOGY: Perspectives on the Treatment of Hematologic and Solid Malignancies.

HLA-A2-positive glioblastoma patients experienced more frequent immune responses to the dendritic-cell immunotherapy IDT-107, responses that may be associated with improved survival.

Adding the EGFR-targeting drug panitumumab to chemotherapy had no effect on survival in a group of patients with wild-type KRAS status advanced biliary tract cancer.

For men with prostate cancer undergoing radiation therapy, consumption of men’s health supplements are unlikely to prevent adverse events, metastasis, or cancer-related death.

New breast cancer screening guidelines from the American Cancer Society recommend pushing the start of screening back by 5 years and screening every other year rather than annually starting at age 55.

The American Society of Clinical Oncology (ASCO) updated their antiemetic guideline to include the use of a novel antiemetic combination for cancer patients.

An analysis of different breast cancer screening schedules suggests that biennial mammograms may be acceptable for postmenopausal women, but that premenopausal women likely need more frequent screening.

This management guide covers the treatment, diagnosis, and staging of prostate cancer.

This management guide covers the risk factors, symptoms, diagnosis, staging, and treatment of liver, gallbladder, and biliary tract cancers using radiation, surgery, and medical treatment.

This testicular cancer management guide covers the diagnosis, staging, and treatment of germ-cell tumors and seminoma.

This comprehensive guide for oncologists covers the diagnosis, staging, treatment, and management of esophageal cancer.

This management guide covers the screening, diagnosis, staging, and treatment of cervical cancers.

Carcinoma of the epithelial lining (endometrium) of the uterine corpus is the most common female pelvic malignancy. Factors influencing its prominence are the declining incidence of cervical cancer, longer life expectancy, and earlier diagnosis.

Malignancies have been detected in approximately 40% of all patients with acquired immunodeficiency syndrome (AIDS) sometime during the course of their illness.

Intracranial neoplasms can arise from any of the structures or cell types present in the cranial vault, including the brain, meninges, pituitary gland, skull, and even residual embryonic tissue.

Carcinoma of an unknown primary site is a common clinical syndrome, accounting for approximately 3% of all oncologic diagnoses. Patients in this group are heterogeneous, having a wide variety of clinical presentations and pathologic findings.

Infections are among the most common, potentially serious complications of cancer and its treatment.

Malignant pleural effusion complicates the care of approximately 150,000 people in the United States each year.

This management guide covers the oncologic emergencies such as superior vena cava syndrome, deep venous thrombosis, pulmonary embolism, and other paraneoplastic syndromes.

Hematopoietic cell transplantation (HCT) is the IV infusion of hematopoietic stem and progenitor cells designed to establish marrow and immune function in patients with a variety of acquired and inherited malignant and nonmalignant disorders.

This management guide covers the symptoms, screening, diagnosis, and treatment of small-cell lung cancer (SCLC), mesothelioma, and thymoma from a surgical, medical, and radiation oncology approach.

Skin cancer is the single most common form of cancer, accounting for more than 75% of all cancer diagnoses. More than 1 million cases of squamous cell and basal cell carcinomas are diagnosed annually, with a lifetime risk of more than one in five.

A treatment strategy including dose intensification with interval compression, use of the most active agents available, and the use of irinotecan as a radiation sensitizer led to a promising event-free survival rate in certain patients with metastatic rhabdomyosarcoma.

Oncologists, whether they like it or not, must develop some psychological skills if they ever hope to master the art of caring for people living with cancer.